Compare LRMR & SAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LRMR | SAR |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 455.8M | 372.7M |
| IPO Year | 2014 | N/A |
| Metric | LRMR | SAR |
|---|---|---|
| Price | $5.00 | $22.60 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 4 |
| Target Price | $16.50 | ★ $23.75 |
| AVG Volume (30 Days) | ★ 2.0M | 108.3K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 14.75% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,816.14 | $0.39 |
| P/E Ratio | ★ N/A | $9.44 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.61 | $20.78 |
| 52 Week High | $6.42 | $25.64 |
| Indicator | LRMR | SAR |
|---|---|---|
| Relative Strength Index (RSI) | 57.54 | 52.58 |
| Support Level | $3.14 | $22.56 |
| Resistance Level | $5.37 | $23.47 |
| Average True Range (ATR) | 0.31 | 0.64 |
| MACD | -0.02 | 0.05 |
| Stochastic Oscillator | 90.66 | 85.69 |
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
Saratoga Investment Corp is a specialty finance company that provides customized financing solutions to U.S. middle-market businesses. The Company invests in senior and unitranche leveraged loans and mezzanine debt, and, to a lesser extent, equity to provide financing for change of ownership transactions, strategic acquisitions, recapitalizations and growth initiatives in partnership with business owners, management teams and financial sponsors. Its objective is to create attractive risk-adjusted returns by generating current income and long-term capital appreciation from its debt and equity investments.